Cargando…

Treatment Goals for Psoriasis as Measured by Patient Benefit Index: Results of a National Psoriasis Foundation Survey

INTRODUCTION: This cross-sectional survey was conducted with National Psoriasis Foundation (NPF) to capture treatment perspectives and expectations in patients with psoriasis (PsO) using Patient Needs Questionnaire (PNQ) of Patient Benefit Index (PBI). METHODS: Adult participants with self-reported...

Descripción completa

Detalles Bibliográficos
Autores principales:	Armstrong, April, Edson-Heredia, Emily, Zhu, Baojin, Burge, Russel, Bell, Stacie, Crowley, Jeffery J., Smith, Stacy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122869/ https://www.ncbi.nlm.nih.gov/pubmed/35399114 http://dx.doi.org/10.1007/s12325-022-02124-2

Ejemplares similares

Cumulative Clinical Benefits of Biologics in the Treatment of Patients with Moderate-to-Severe Psoriasis over 1 Year: a Network Meta-Analysis
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Cost per cumulative clinical benefit of biologic therapies for patients with plaque psoriasis: a systematic review
por: Blauvelt, Andrew, et al.
Publicado: (2021)

Quality of Life and Work Productivity Impairment among Psoriasis Patients: Findings from the National Psoriasis Foundation Survey Data 2003–2011
por: Armstrong, April W., et al.
Publicado: (2012)

Relationship Between Rapid Skin Clearance and Quality of Life Benefit: Post Hoc Analysis of Japanese Patients with Moderate-to-Severe Psoriasis Treated with Ixekizumab (UNCOVER-J)
por: Honma, Masaru, et al.
Publicado: (2020)

The Development of the Genital Psoriasis Sexual Frequency Questionnaire (GenPs-SFQ) to Assess the Impact of Genital Psoriasis on Sexual Health
por: Gottlieb, Alice B., et al.
Publicado: (2017)

The Development of a Patient-Reported Outcome Measure for Assessment of Genital Psoriasis Symptoms: The Genital Psoriasis Symptoms Scale (GPSS)
por: Gottlieb, Alice B., et al.
Publicado: (2017)

Treatment Persistence of Ixekizumab in Adults with Moderate-to-Severe Plaque Psoriasis Participating in the Canadian Patient Support Program
por: Gulliver, Wayne, et al.
Publicado: (2022)

Clinical Goals and Barriers to Effective Psoriasis Care
por: Strober, Bruce E., et al.
Publicado: (2018)

A Retrospective Cohort Analysis of Treatment Patterns Over 1 Year in Patients with Psoriasis Treated with Ixekizumab or Guselkumab
por: Blauvelt, Andrew, et al.
Publicado: (2022)

National Psoriasis Foundation Telemedicine Task Force guidance for management of psoriatic disease via telemedicine
por: Pelet del Toro, Natalia, et al.
Publicado: (2023)

National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1
por: Gelfand, Joel M., et al.
Publicado: (2020)

Drug survival of ixekizumab, TNF inhibitors, and other IL‐17 inhibitors in real‐world patients with psoriasis: The Corrona Psoriasis Registry
por: Lockshin, Benjamin, et al.
Publicado: (2021)

Psoriasis Severity Assessment Combining Physician and Patient Reported Outcomes: The Optimal Psoriasis Assessment Tool
por: Leonardi, Craig, et al.
Publicado: (2021)

Demographic and Clinical Factors Associated with Patient-Reported Remission in Psoriasis
por: Gondo, George, et al.
Publicado: (2022)

Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab
por: Blauvelt, Andrew, et al.
Publicado: (2020)

Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support Program
por: Gottlieb, Alice B., et al.
Publicado: (2023)

Epidemiology of psoriasis in hard-to-treat body locations: data from the Danish skin cohort
por: Egeberg, Alexander, et al.
Publicado: (2020)

Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry
por: Lockshin, Benjamin, et al.
Publicado: (2022)

Healthcare Costs Among Patients with Psoriasis Treated with Ixekizumab Versus Secukinumab in Real-World Settings Over 24 Months
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Association Between Poor Sleep and Myocardial Infarction in Patients with Psoriasis: Findings from a Cross-Sectional Study with the National Psoriasis Foundation
por: Spencer, Riley K., et al.
Publicado: (2023)

Real-World Biologic Adherence, Persistence, and Monotherapy Comparisons in US Patients with Psoriasis: Results from IBM MarketScan(®) Databases
por: Leonardi, Craig, et al.
Publicado: (2022)

Dynamic Visual Representation of Clinical Efficacy of Ixekizumab in Psoriasis
por: Hawkes, Jason E., et al.
Publicado: (2021)

Comparison of Real-World Treatment Patterns Among Biologic-Experienced Patients with Psoriasis Treated with Ixekizumab or Secukinumab Over 18 Months
por: Blauvelt, Andrew, et al.
Publicado: (2021)

Outcomes of Biologic Use in Asian Compared with Non-Hispanic White Adult Psoriasis Patients from the CorEvitas Psoriasis Registry
por: Yu, Chen, et al.
Publicado: (2022)

Real-world health outcomes in adults with moderate-to-severe psoriasis in the United States: a population study using electronic health records to examine patient-perceived treatment effectiveness, medication use, and healthcare resource utilization
por: Armstrong, April W., et al.
Publicado: (2018)

Patients’ Perspectives on the Impact of Genital Psoriasis: A Qualitative Study
por: Cather, Jennifer Clay, et al.
Publicado: (2017)

Comparison of Real-World Costs, Healthcare Resource Utilization, and Comorbidity-Related Costs Between Ixekizumab and Secukinumab Among Biologic-Experienced Patients with Psoriasis Over 18 Months in the USA
por: Blauvelt, Andrew, et al.
Publicado: (2023)

Treatment Options and Goals for Patients with Generalized Pustular Psoriasis
por: Krueger, James, et al.
Publicado: (2022)

JAK Inhibitors: Treatment Efficacy and Safety Profile in Patients with Psoriasis
por: Hsu, Leeyen, et al.
Publicado: (2014)

Correlation of Psoriasis Disability Index and Psoriasis Area and Severity Index: A Study from Afghanistan
por: Aalemi, Ahmad Khalid, et al.
Publicado: (2022)

A Clinician’s Guide to the Diagnosis and Treatment of Candidiasis in Patients with Psoriasis
por: Armstrong, April W., et al.
Publicado: (2016)

Practices and perspectives on medical cannabis and cannabinoids: A survey of the National Psoriasis Foundation Medical Advisory Board
por: Nussbaum, Dillon, et al.
Publicado: (2022)

Long-Term Benefit–Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis
por: Armstrong, April W., et al.
Publicado: (2021)

Viewing Psoriasis as a Systemic Disease for Better Health Outcomes
por: Gondo, George C., et al.
Publicado: (2021)

Effect of Age of Onset of Psoriasis on Clinical Outcomes with Systemic Treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
por: Singh, Sanminder, et al.
Publicado: (2018)

An update on psoriasis and metabolic syndrome: A meta-analysis of observational studies
por: Singh, Sanminder, et al.
Publicado: (2017)

National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2—Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments
por: Gelfand, Joel M., et al.
Publicado: (2021)

US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey
por: Lebwohl, Mark G., et al.
Publicado: (2015)

Psoriasis comorbidities: complications and benefits of immunobiological treatment
por: de Carvalho, André Vicente Esteves, et al.
Publicado: (2016)

Reliability and validity of the Chinese version of the Psoriasis Disability Index (PDI) in Chinese patients with psoriasis
por: He, Zehui, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_kt608np2ujvm11rqt4qc2evdhj